Definitive Healthcare

Overview

Definitive Healthcare is a “healthcare commercial intelligence” platform founded in 2011 by Jason Krantz. The company went public September 15, 2021 on Nasdaq at an implied valuation of ~$3.9 billion. Its core proposition: translating fragmented healthcare data — claims, provider affiliations, prescribing behavior, institutional financials, expert networks — into actionable targeting and market insight for life sciences commercial teams, medical device companies, and healthcare technology firms.

As of year-end 2025: ~$241.5M annual revenue, ~2,500 customers, 682 employees. Market cap has collapsed from $4B+ post-IPO to $150-160M as of early April 2026 ($1.00-$1.10/share), reflecting prolonged revenue growth deceleration and accelerating customer churn. The stock has lost more than 97% of its peak value.

Services & Capabilities

The Atlas Dataset

Unified data layer underpinning all products, introduced February 2023:

• Atlas Reference & Affiliation: 16M+ healthcare professionals, 330,000+ organizations, 1.5M+ healthcare executive contacts. Covers hospitals, physician groups, ASCs, imaging centers, LTC facilities.
• Atlas All-Payor Claims: Billions of de-identified hospital and medical claims (commercial, Medicare, Medicaid). Supports procedure code search, diagnosis-level market sizing, referral pattern mapping, competitor share analysis.
• Atlas Prescription Claims: All-payor lifecycle pharmacy and prescription claims including paid, rejections, and reversals. Primary dataset for HCP prescribing behavior analysis and call plan design.
• Atlas Expert: 13M+ KOL/researcher profiles enriched with publications, clinical trials, presentations, grants, social media, advisory boards.

Product Suite

• View Suite (HospitalView, PhysicianView, GroupView): Provider/organization intelligence with claims overlay
• PatientFinder (Latitude Reporting): Real-time custom patient cohorts by disease state
• Expert Analytics: KOL landscape mapping for medical affairs
• Advanced Analytics & Professional Services: Custom analytics (5% of revenue, growing 49% YoY)
• Populi Suite (acquired August 2023, $52M): Population Intelligence, Market Intelligence, Provider Intelligence for health systems

Pharma Commercial Use Cases

Territory/call plan design, launch TAM sizing, KOL mapping, market access intelligence (formulary decision-maker targeting), competitive intelligence. Pricing: ~$30,000-$150,000+/year — below IQVIA enterprise contracts but above general-purpose sales intelligence tools.

Competitive Position

Definitive Healthcare is caught between scaled incumbents with deeper resources and well-funded private challengers with more advanced technology.

vs. IQVIA

IQVIA generates $15B+ annual revenue versus DH’s $241M — scale gap translates to data acquisition budgets, enterprise sales leverage, and multi-product bundling. IQVIA’s OneKey: 25M+ HCPs, 6M HCOs globally. DH’s advantage: richer U.S. hospital/health system operational intelligence (financials, technology profiles, executive contacts) and self-service accessibility.

vs. Komodo Health

Komodo Health competes directly on patient-level analytics, HCP targeting, and market sizing. Komodo’s Healthcare Map (330M+ patients) with AI/ML tooling has won share among data-sophisticated buyers, particularly in specialty/rare disease. With no public market pressure, Komodo invests aggressively in R&D. DH retains advantages in platform breadth across provider/payer/hospital contexts and established customer base.

vs. Veeva OpenData

Veeva OpenData is a global HCP/HCO reference product deeply integrated into Veeva CRM workflows. DH serves analytics and targeting discovery; Veeva serves CRM data stewardship. Partially complementary, but as Veeva builds analytics capabilities the boundary narrows.

Vendor	Primary Strength	DH Overlap	Relative Threat
IQVIA	Global HCP data + pharma analytics at scale	High	Very High
Komodo Health	Longitudinal patient data, AI-native	High	High
Veeva OpenData	CRM-native HCP reference data	Moderate	Growing
ZoomInfo Healthcare	Low-cost B2B healthcare contacts	Low-Moderate	Low (for pharma)

Recent Developments

• CEO Transition (June 2024): Kevin Coop (ex-DailyPay CEO, Dun & Bradstreet President NA) appointed CEO. Third CEO since 2021; average management tenure ~1.2 years.
• Claims Data Disruption (2024): Data sourcing issues triggered customer dissatisfaction and elevated churn. New claims source introduced by Q4 2025, volumes restored.
• Net Dollar Retention Deterioration: All-customer NDR: 91% (2023) to 85% (2024) to 81% (2025). Enterprise NDR: 97% (2023) to 90% (2024) to 85% (2025). Platform at 81% NDR is actively contracting.
• Goodwill Impairment: Cumulative ~$885M across 2024-2025 ($688.9M + $196.1M), formally acknowledging acquisition values overstated durable economic value.
• Revenue Contraction: From $251.4M (2023) to $252.2M (2024) to $241.5M (2025). Guided $220-226M for 2026 (-6 to -9%).
• Platform Integrations (2025): Enhanced data integrations with Snowflake, Databricks, HubSpot — defensive response to data commoditization risk.

Financial Profile

Metric	FY2023	FY2024	FY2025	FY2026E
Revenue	$251.4M	$252.2M	$241.5M	$220-226M
YoY Growth	+12.9%	+0.3%	-4.2%	-6 to -9%
Adjusted EBITDA	—	$79.1M (31%)	$70.4M (29%)	$53-58M (24-26%)
GAAP Net Loss	—	—	$(199.3M)	—
Free Cash Flow	—	—	$54.9M	—
Enterprise Customers (>$100K)	—	555	511	—
Net Dollar Retention	91%	85%	81%	—

Cash: $180.9M. Total debt: $166.3M. Advent International holds 42.7% (62.5M shares). Stock at $1.00/share ($150M market cap) trades at ~0.6x trailing revenue — deep distress for SaaS. Going-private speculation exists but no formal process disclosed.

Sources

Primary source: raw/research/06_definitive_healthcare.md. Financial data from Definitive Healthcare SEC filings and earnings releases. Market data from Stock Titan, Yahoo Finance, Investing.com, KoalaGains, Provyx.